• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Metformin linked to decreased BMI z scores in prepubertal children

byMatthew Lin, MDandCordelia Ross
June 12, 2017
in Chronic Disease, Endocrinology, Pediatrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Prepubertal obese children treated with metformin over 6 months had significantly lower BMI z scores compared to those receiving placebo. These differences were not present in pubertal children.

2. Prepubertal obese children treated with metformin over 6 months had higher qualitative insulin-sensitivity check index (QUICKI), or lower rates of insulin resistance, compared to those receiving placebo. Additionally, prepubertal obese children had lower concentrations of INF-gamma and tPAI-1 at 6 months compared to prepubertal children on placebo.

Evidence Rating: 1 (Excellent)

Study Rundown: Obesity and diabetes are an increasing problem in the pediatric population. Metformin is an established oral antihyperglycemic agent approved for the treatment of adults with type 2 diabetes mellitus and in children >10 years of age. In adults, metformin has been shown to significantly reduce obesity. Similar existing trials in pediatric patients have not taken into consideration the stages of puberty as a confounding factor in the effects of metformin on weight loss. In this study, researchers investigated whether treatment with oral metformin is capable of reducing BMI z score, insulin sensitivity and inflammatory biomarkers in obese children, while stratifying for pubertal stage by Tanner staging. Researchers found an exclusive significant decrease in BMI z score in prepubertal children in the metformin group compared to the placebo group at 6 months. Additionally, prepubertal children in the metformin group had significantly lower scores of insulin resistance and lower concentrations of pro-inflammatory markers, including INF-gamma and tPAI-1. The authors suggest that the lack of significant results observed in the pubertal group may be due to the well-known decrease in insulin sensitivity known to occur in this population. Limitations of the study include medication compliance assessment by pill bottle return, as opposed to pill counting, and difficulty in assessing the effects of lifestyle changes in the children throughout the study. These results suggest that while metformin offers several metabolic benefits in prepubertal children, puberty itself may impact the extent of these effects.

Click to read the study, published today in Pediatrics

Relevant Reading: Metformin and body weight

In-Depth [randomized controlled trial]: Participants in this randomized, double-blind, placebo-control trial included 140 children (82 boys, 68 girls) across 4 Spanish hospitals. The primary outcome was BMI z score compared to baseline after 6 months. Secondary outcomes included insulin resistance and concentrations of inflammatory markers. In the prepubertal population, BMI z scores were significantly decreased in the metformin group when compared to placebo (P = 0.04). Baseline and 6 month BMI z scores were 4.0 ± 0.2 and 3.4 ± 0.2 for the placebo group, and 3.4 ± 0.2 and 2.6 ± 0.20 for the metformin group. Such significant differences were not observed in the pubertal group. Additionally, binary logistic regression showed an independent association between BMI z score and metformin treatment (OR = 0.18 [95% CI = 0.050-0.636; P = 0.01]. Insulin sensitivity was determined using the Qualitative insulin-sensitivity check index (QUICKI) – a measure of insulin resistance based on fasting glucose and insulin levels, with lower levels indicating resistance. Prepubertal children in the metformin group had significantly increased QUICKI scores compared to those receiving placebo (P = 0.01). No significant differences were seen in the pubertal group. Of the inflammatory markers tested, prepubertal children had lower concentrations of INF-gamma (P = 0.02) and tPAI-1 (P = 0.04). Again, these significant differences were not seen in pubertal children.

RELATED REPORTS

School nutritional quality programs associated with lower BMI in children

Screen time and sedentary lifestyle associated with increased obesity rates among adolescents

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BMIchildhood obesitymetformin
Previous Post

Next-generation metagenomics sequencing may sleuth out hard-to-find viruses in the blood

Next Post

Tofacitinib may be an effective treatment for nail psoriasis

RelatedReports

Eating in the absence of hunger linked to toddler obesity
Chronic Disease

School nutritional quality programs associated with lower BMI in children

March 6, 2023
Sleep duration inversely related to childhood type 2 diabetes risk makers
Chronic Disease

Screen time and sedentary lifestyle associated with increased obesity rates among adolescents

February 24, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

January 25, 2023
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

Weekly semaglutide associated with reduced BMI in adolescents with obesity

December 26, 2022
Next Post
Long-term use of apremilast for psoriasis associated with an acceptable safety profile

Tofacitinib may be an effective treatment for nail psoriasis

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

Lithium during pregnancy linked to modest increase in cardiac malformations

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

Complete dissection does not increase survival for sentinel-node positive melanoma patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Active surveillance strategies to improve rates of inferior vena cava filter retrieval
  • Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response
  • Hydrochlorothiazide does not impact risk of kidney-stone recurrence
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options